. 2020 Oct 14;12(10):963. doi: 10.3390/pharmaceutics12100963

Table 3.

Peptide/protein-based therapies in clinical trials for neurological diseases.

Name	Description	Condition/Disease	Route of Administration	Status	Reference/Clinical Trial Identifier
Aducanumab	Human monoclonal antibody targeting Aβ	Alzheimer’s disease	i.v.	Phase III (under review)	NCT02477800; NCT02484547
Gantenerumab	Human IgG1 antibody targeting Aβ	Alzheimer’s disease	s.c.	Phase III	NCT01224106; NCT01760005; NCT02051608; NCT03443973; NCT03444870
ABBV-8E12	Humanized IgG4 anti-tau antibody	Alzheimer’s disease	i.v.	Phase II	NCT02880956
AL002	Anti-human TREM2 antibody	Alzheimer’s disease	i.v.	Phase I	NCT03635047
AL003	Anti-human SIGLEC 3 antibody	Alzheimer’s disease	i.v.	Phase I	NCT03822208
Crenezumab	Humanized IgG4 monoclonal antibody targeting Aβ	Alzheimer’s disease	i.v.	Phase II	NCT01397578; NCT01343966; NCT01723826; NCT01998841; NCT02670083
Donanemab	Humanized IgG1 monoclonal antibody targeting N3pG- Aβ	Alzheimer’s disease	i.v.	Phase II	NCT03367403
JNJ-63733657	Monoclonal antibody targeting the mid-region of tau	Alzheimer’s disease	i.v.	Phase I	NCT03375697
Semorinemab	Anti-tau IgG4 antibody	Alzheimer’s disease	i.v.	Phase II	NCT02820896; NCT03828747; NCT03289143
Solanezumab	Humanized monoclonal IgG1 antibody	Alzheimer’s disease	i.v.	Phase III	NCT00329082; NCT00749216; NCT00904683; NCT00905372; NCT01148498; NCT01127633; NCT01760005; NCT01900665; NCT02008357; NCT02760602
Zagotenemab	Humanized anti-tau antibody	Alzheimer’s disease	i.v.	Phase II	NCT03518073
Opicinumab	Monoclonal antibody targeting LINGO1	Multiple sclerosis	i.v.	Phase II	NCT02833142; NCT03222973; NCT01721161
Rindopepimut	EGFRvIII peptide vaccine	Glioblastoma	i.d.l	Phase II	NCT01480479; NCT01498328; NCT00458601
Durvalumab	Human IgG1κ monoclonal antibody	Glioblastoma	i.v.	Phase II	NCT02336165
¹²⁵I-MAB-425	Anti-epidermal growth factor receptor-425 monoclonal antibody	Glioblastoma	i.v. or i.a.	Phase II	NCT01317888
¹³¹I-chTNT-1/B MAb	Monoclonal antibody targeting DNA-histone H1 complex	Glioblastoma	s.c.	Phase II	NCT00677716; NCT00509301; NCT00128635; NCT00004017
¹⁸⁸Re-labeled Nimotuzumab	Humanized monoclonal antibody targeting epidermal growth factor receptors	Glioblastoma and astrocytoma	Intracavity	Phase I	[227]
²¹¹At-labeled 81C6 mAb	Chimeric antitenascin monoclonal antibody	Brain tumor	Intracavity	Phase I	[228]; NCT00003461
¹³¹I-Omburtamab	Murine monoclonal antibody targeting 4Ig-B7-H3	Neuroblastoma and leptomeningeal metastases	i.c.v.	Phase II/III	[229]; NCT03275402

TREM2: triggering receptor expressed on Myeloid cells-2; SIGLEC: sialic acid binding Ig-like lectins; LINGO: nogo receptor-interacting protein; EGFR: epidermal growth factor receptor; i.c.v.: intracerebroventricular; s.c.: subcutaneous; i.v.: intravenous; i.d.: intradermal; i.a.: intraarterial.